Evidence map›Paper›PMID 28695391›Full record

ArticleAnnals of surgical oncology2017

Challenging the principle of utility as a barrier for wider use of liver transplantation for hepatocellular cancer.

Michał Grąt, Jan Stypułkowski, Waldemar Patkowski, Karolina M Wronka, Emil Bik, Maciej Krasnodębski, Łukasz Masior, Zbigniew Lewandowski, Michał Wasilewicz, Karolina Grąt and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Annals of surgical oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Observational
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Michał GrątDepartment of General, Transplant and Liver Surgery, Medical University of Warsaw, Warsaw, Poland. michal.grat@gmail.com.
Jan StypułkowskiDepartment of General, Transplant and Liver Surgery, Medical University of Warsaw, Warsaw, Poland.
Waldemar PatkowskiDepartment of General, Transplant and Liver Surgery, Medical University of Warsaw, Warsaw, Poland.
Karolina M WronkaDepartment of General, Transplant and Liver Surgery, Medical University of Warsaw, Warsaw, Poland.
Emil BikDepartment of General, Transplant and Liver Surgery, Medical University of Warsaw, Warsaw, Poland.
Maciej KrasnodębskiDepartment of General, Transplant and Liver Surgery, Medical University of Warsaw, Warsaw, Poland.
Łukasz MasiorDepartment of General, Transplant and Liver Surgery, Medical University of Warsaw, Warsaw, Poland.
Zbigniew LewandowskiDepartment of Epidemiology, Medical University of Warsaw, Warsaw, Poland.
Michał WasilewiczHepatology and Internal Medicine Unit, Department of General, Transplant and Liver Surgery, Medical University of Warsaw, Warsaw, Poland.
Karolina GrątSecond Department of Clinical Radiology, Medical University of Warsaw, Warsaw, Poland.
Marek KrawczykDepartment of General, Transplant and Liver Surgery, Medical University of Warsaw, Warsaw, Poland.
Krzysztof ZieniewiczDepartment of General, Transplant and Liver Surgery, Medical University of Warsaw, Warsaw, Poland.
Medical University of Warsaw · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlthough transplant benefit appears superior for patients with advanced hepatocellular cancer (HCC), liver transplantation remains limited to selected low-risk HCC patients to keep their outcomes similar to heterogeneous group of non-HCC patients. The purpose of this study was to assess the rationale for current policy of restricting access to liver transplantation to minority of HCC patients based on utility principle.

methodsThis retrospective cohort study comprised 1246 liver transplant recipients, including 206 HCC and 1040 non-HCC patients. Patient survival was the primary outcome measure. Patients with HCC and benign diseases were divided into low-, moderate-, and high-risk subgroups basing on independent risk factors for disease-free survival and model for end-stage liver disease (MELD) score (<30, 30-40, >40), respectively.

resultsMELD (p < 0.001) and presence of HCC (p = 0.008) were independent risk factors for early and late mortality, respectively. Total tumor volume (p = 0.008) and alpha-fetoprotein (p = 0.013) were independent predictors of recurrence and mortality used for division of HCC patients into low-, moderate-, and high-risk subgroups, with disease-free survival rates of 74.9% (5 years), 51.7% (5 years), and 8.0% (3 years), respectively (p < 0.001). There were no differences in 5-year overall survival between low-risk HCC (74.9%) and non-HCC (81.9%) patients (p = 0.210), moderate-risk HCC (63.3%) and non-HCC (68.0%) patients (p = 0.372), and high-risk HCC (55.0%) and non-HCC (56.0%) patients (p = 0.559).

conclusionsThe principle of utility is unequally applied for restriction of access to liver transplantation for HCC patients. The results provide rationale for discussion on reinitiation of liver transplantation for advanced HCCs.

Indexed as

Patient SelectionAgedalpha-FetoproteinsAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, HepatocellularFemaleFollow-Up StudiesHumansLiver NeoplasmsLiver TransplantationMaleMiddle AgedNeoplasm Recurrence, LocalPrognosisResource AllocationRetrospective Studiesalpha-Fetoproteins

Identifiers

PMID28695391
PMCPMC5596049
OpenAlexW2735306446

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.